Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells

Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder. Current targeted therapies designed to inhibit the tyrosine kinase activity of the BCR-ABL oncoprotein have made a significant breakthrough in the treatment of CML patients. However, CML remains a chronic disease that a patient...

Full description

Saved in:
Bibliographic Details
Published in:Stem Cells International 2013-01, Vol.2013 (2013), p.421-432
Main Authors: Hamad, Ahmad, Sahli, Zeyad, El Sabban, Maya, Mouteirik, Maha, Nasr, Rihab
Format: Article
Language:English
Subjects:
Care and treatment
Chronic myeloid leukemia
Development and progression
Health aspects
Medical case management
Prognosis
Review
Stem cell research
Stem cells
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder. Current targeted therapies designed to inhibit the tyrosine kinase activity of the BCR-ABL oncoprotein have made a significant breakthrough in the treatment of CML patients. However, CML remains a chronic disease that a patient must manage for life. Although tyrosine kinase inhibitors (TKI) therapy has completely transformed the prognosis of CML, it has made the therapeutic management more complex. The interruption of TKI treatment results in early disease progression because it does not eliminate quiescent CML stem cells which remain a potential reservoir for disease relapse. This highlights the need to develop new therapeutic strategies for CML to achieve a permanent cure, and to allow TKI interruption. This review summarizes recent research done on alternative targeted therapies with a particular focus on some important signaling pathways (such as Alox5, Hedgehog, Wnt/b-catenin, autophagy, and PML) that have the potential to target CML stem cells and potentially provide cure for CML.
ISSN:1687-966X
1687-9678
1687-9678
DOI:10.1155/2013/724360